Published in Pharmacogenet Genomics on January 01, 2010
Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36
Platelet aggregation pathway. Pharmacogenet Genomics (2011) 1.04
Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag (2015) 0.90
Pharmacogenomics of anti-platelet and anti-coagulation therapy. Curr Cardiol Rep (2013) 0.81
Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol (2012) 0.80
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol (2015) 0.79
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med (2015) 0.79
Pharmacogenomics and cardiovascular disease. Curr Cardiol Rep (2013) 0.79
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? Cardiol Res Pract (2013) 0.79
Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese. BMC Med Genet (2014) 0.77
Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. Eur J Clin Pharmacol (2012) 0.77
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines. Ann Lab Med (2017) 0.75
A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes. Int J Clin Exp Med (2015) 0.75
Genetic Determinants of P2Y12 Inhibitors and Clinical Implications. Interv Cardiol Clin (2017) 0.75
CYP2C19(⁎)2 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls. Biomed Res Int (2017) 0.75
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med (2013) 4.27
Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med (2010) 3.32
Instrumental variables: application and limitations. Epidemiology (2006) 3.03
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (2011) 2.68
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA (2010) 2.47
VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther (2006) 2.19
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. J Hypertens (2009) 2.14
Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. Eur Heart J (2006) 2.12
Depressive symptoms in subjects with diagnosed and undiagnosed type 2 diabetes. Psychosom Med (2007) 2.09
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J (2010) 2.00
Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation (2003) 1.96
Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol (2011) 1.94
Risk of hip/femur fracture after stroke: a population-based case-control study. Stroke (2009) 1.88
Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. BMJ (2011) 1.72
Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. Eur Heart J (2012) 1.67
Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. Arch Intern Med (2012) 1.66
Changes in mortality patterns following total hip or knee arthroplasty over the past two decades: a nationwide cohort study. Arthritis Rheumatol (2014) 1.61
Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther (2004) 1.60
Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens (2005) 1.58
Intracoronary infusion of autologous mononuclear bone marrow cells in patients with acute myocardial infarction treated with primary PCI: Pilot study of the multicenter HEBE trial. Catheter Cardiovasc Interv (2008) 1.58
The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost (2009) 1.56
Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest (2013) 1.55
Variation in Renin-Angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. Am J Hypertens (2009) 1.50
Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost (2008) 1.48
Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother (2005) 1.47
Predictors and outcome of grade 3 ischemia in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Electrocardiol (2011) 1.45
Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum (2011) 1.43
Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis (2004) 1.43
Late coronary stent thrombosis complicating urologic surgery. Eur Urol (2007) 1.40
Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med (2008) 1.30
Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis (2011) 1.27
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics (2009) 1.25
Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother (2005) 1.23
Statins accelerate the onset of collagen type II-induced arthritis in mice. Arthritis Res Ther (2012) 1.18
Comparison of different pain scoring systems in critically ill patients in a general ICU. Crit Care (2008) 1.12
Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS One (2010) 1.11
Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf (2005) 1.09
Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. Eur Heart J (2013) 1.08
Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res (2008) 1.07
Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiol Drug Saf (2009) 1.07
Increased mortality by digoxin in patients with atrial fibrillation? J Am Coll Cardiol (2015) 1.07
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J (2011) 1.07
Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol (2005) 1.03
The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens (2004) 1.03
Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Des (2010) 1.02
Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med (2013) 1.02
Systematic differences in treatment effect estimates between propensity score methods and logistic regression. Int J Epidemiol (2008) 1.01
Drug therapy for prevention of recurrent myocardial infarction. Ann Pharmacother (2003) 1.01
Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J (2006) 1.01
Measuring balance and model selection in propensity score methods. Pharmacoepidemiol Drug Saf (2011) 0.99
The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin (2008) 0.99
Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay. EuroIntervention (2011) 0.97
Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol (2011) 0.97
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br J Clin Pharmacol (2014) 0.97
The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics (2012) 0.97
Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol (2005) 0.96